A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389) a potent, oral histamine H4, receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults

T. Werfel, V. Lynch, A. Asher, A. Tsianakas, B. Gupta, R. Sarmiento, A. Ploszczuk, B. Majorek-Olechowska, B. Cimoszko,Arjen Nikkels, T. Hofman, P. Staubach, K. Breuer, A. Gawlik, K. Buczylko, Ma. Morren, G. Layton,M. Yeadon, L. Whitlock, L. Purkins, W. Liu

ALLERGY（2016）

引用 22|浏览2